EMA Reorganizes
EMA restructures organization.
The
The Agency expects to complete the full transition period for the new structure and the revised operating processes in 2014. In the meantime, it will ensure continuity of operations for the evaluation and supervision of medicines.
The agency is creating four new divisions that will support and focus on research and development; evaluate lifecycle management; develop procedures for management and business data; and inspections and pharmacovigilance.
EMA will announce details of the new structure of the organization in September 2013.
Source:
European Medicines Agency
Newsletter
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

